Company profile

Michael R. McMullen
Fiscal year end
Former names
IRS number

A stock data



1 Sep 20
1 Dec 20
31 Oct 21


Quarter (USD) Jul 20 Apr 20 Jan 20 Jul 19
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Oct 19 Oct 18 Oct 17 Oct 16
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Agilent earnings reports.

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
19 Nov 20 Henrik Ancher-Jensen Common Stock Payment of exercise Dispose F No 108.68 5,098 554.05K 91,694.985
19 Nov 20 Gonsalves Rodney Common Stock Payment of exercise Dispose F No 108.68 2,673 290.5K 44,021.092
19 Nov 20 Grau Dominique Common Stock Payment of exercise Dispose F No 108.68 7,306 794.02K 98,184.616
19 Nov 20 Padraig Mcdonnell Common Stock Payment of exercise Dispose F No 108.68 821 89.23K 18,849
19 Nov 20 Robert W. McMahon Common Stock Payment of exercise Dispose F No 108.68 1,751 190.3K 79,123
86.2% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 722 712 +1.4%
Opened positions 77 100 -23.0%
Closed positions 67 74 -9.5%
Increased positions 254 231 +10.0%
Reduced positions 246 231 +6.5%
13F shares
Current Prev Q Change
Total value 27.43B 23.63B +16.1%
Total shares 263.68M 267.22M -1.3%
Total puts 1.04M 1.23M -15.0%
Total calls 2.36M 1.06M +122.6%
Total put/call ratio 0.4 1.2 -61.8%
Largest owners
Shares Value Change
BLK Blackrock 24.81M $2.5B +1.0%
Vanguard 24.26M $2.45B -2.0%
TROW T. Rowe Price 23.69M $2.39B -1.2%
STT State Street 13.65M $1.38B -1.3%
Pershing Square Capital Management 12.25M $1.24B -3.0%
Wellington Management 8.6M $868.31M -0.5%
Harris Associates L P 5.83M $588.02M -6.7%
IVZ Invesco 5.43M $547.67M -3.0%
Artisan Partners Limited Partnership 5.4M $545.03M +0.0%
Geode Capital Management 4.99M $502.84M +0.9%
Largest transactions
Shares Bought/sold Change
Voya Investment Management 2.04M +1.34M +188.7%
First Trust Advisors 505.91K -1.25M -71.3%
GS Goldman Sachs 956.93K -901.05K -48.5%
D. E. Shaw & Co. 2.61M -838K -24.3%
Marshall Wace 2.31M +736.54K +46.9%
Allianz Asset Management GmbH 2.63M -709.58K -21.3%
BlueSpruce Investments 2.8M +661.82K +31.0%
JHG Janus Henderson 417.52K -652.56K -61.0%
CMTDF Sumitomo Mitsui Trust 1.2M -640.16K -34.7%
KBCSF KBC 453.52K -551.13K -54.9%

Financial report summary

  • Our operating results and financial condition could be harmed if the markets into which we sell our products decline or do not grow as anticipated.
  • If we do not introduce successful new products and services in a timely manner to address increased competition through frequent new product and service introductions, rapid technological changes and changing industry standards, our products and services may become obsolete, and our operating results may suffer.
  • General economic conditions may adversely affect our operating results and financial condition.
  • Failure to adjust our purchases due to changing market conditions or failure to accurately estimate our customers' demand could adversely affect our income.
  • Demand for some of our products and services depends on the capital spending policies of our customers, research and development budgets and on government funding policies.
  • Economic, political, foreign currency and other risks associated with international sales and operations could adversely affect our results of operations.
  • Our strategic initiatives to adjust our cost structure could have long-term adverse effects on our business, and we may not realize the operational or financial benefits from such actions.
  • Our business will suffer if we are not able to retain and hire key personnel.
  • Our acquisitions, strategic investments and alliances, joint ventures, exiting of businesses and divestitures may result in financial results that are different than expected.
  • If we fail to maintain an effective system of internal controls, we may not be able to accurately report our financial results, which could lead to a loss of investor confidence in our financial statements and have an adverse effect on our stock price.
  • Our customers and we are subject to various governmental regulations. Compliance with or changes in such regulations may cause us to incur significant expenses, and if we fail to maintain satisfactory compliance with certain regulations, we may be forced to recall products and cease their manufacture and distribution, and we could be subject to civil or criminal penalties.
  • We are subject to extensive regulation by the FDA and certain similar foreign regulatory agencies, and failure to comply with such regulations could harm our reputation, business, financial condition and results of operations.
  • Some of our products are subject to particularly complex regulations such as regulations of toxic substances, and failure to comply with such regulations could harm our business.
  • Our business may suffer if we fail to comply with government contracting laws and regulations.
  • Our retirement and post retirement pension plans are subject to financial market risks that could adversely affect our future results of operations and cash flows.
  • The impact of consolidation and acquisitions of competitors is difficult to predict and may harm our business.
  • If we are unable to successfully manage the consolidation and streamlining of our manufacturing operations, we may not achieve desired efficiencies, and our ability to deliver products to our customers could be disrupted.
  • Our operating results may suffer if our manufacturing capacity does not match the demand for our products.
  • Dependence on contract manufacturing and outsourcing other portions of our supply chain, including logistics and third-party package delivery services, may adversely affect our ability to bring products to market and damage our reputation. Dependence on outsourced information technology and other administrative functions may impair our ability to operate effectively.
  • Environmental contamination from past and ongoing operations could subject us to substantial liabilities.
  • Third parties may claim that we are infringing their intellectual property, and we could suffer significant litigation or licensing expenses or be prevented from selling products or services.
  • Third parties may infringe our intellectual property, and we may suffer competitive injury or expend significant resources enforcing our rights.
  • Changes in tax laws, unfavorable resolution of tax examinations, or exposure to additional tax liabilities could have a material adverse effect on our results of operations, financial condition and liquidity.
  • If tax incentives change or cease to be in effect, our income taxes could increase significantly.
  • We have outstanding debt and may incur other debt in the future, which could adversely affect our financial condition, liquidity and results of operations.
  • If we suffer a loss to our factories, facilities or distribution system due to catastrophe, our operations could be seriously harmed.
  • If we experience a significant disruption in, or breach in security of, our information technology systems, or if we fail to implement new systems and software successfully, our business could be adversely affected.
  • Adverse conditions in the global banking industry and credit markets may adversely impact the value of our cash investments or impair our liquidity.
  • Regulations related to “conflict minerals” may cause us to incur additional expenses and could limit the supply and increase the cost of certain metals used in manufacturing our products.
  • We cannot assure that we will continue to pay dividends on our common stock.
Content analysis ?
H.S. sophomore Avg
New words: aforementioned, annum, bear, care, consumption, COVID, dramatically, euro, feedback, geography, gradual, heavily, incomplete, incorrect, insufficient, low, pace, pose, premature, ramping, recovery, resilience, resume, resumed, safe, sequentially, stemming, sustainability, weak
Removed: amounted, invoicing, transferred


Use of Tri- and Tetra- Hydroxyl Quaternary Ammonium Compounds As Resolving Agents for Electrophoretic Separations
26 Nov 20
The present disclosure provides methods of improving the resolution of analytes by in electrophoretic separations using a gel by incorporating into the gel an effective amount of one or more tri- or tetra-hydroxyl quaternary ammonium compounds, or a mixture of such compounds.
Stable Label Isotope Tracing for Untargeted Data
19 Nov 20
A method for analyzing samples utilizing stable label isotope tracing includes receiving mass spectrometry (MS) data generated by an MS system performing untargeted data acquisition on a plurality of samples, performing untargeted feature extraction on the unlabeled compound data to generate a data set of first extracted features, generating a plurality of empirical molecular formulas respectively corresponding to the first extracted features, performing targeted isotopologue extraction on the labeled compound data to generate a data set of second extracted features, wherein the targeted isotopologue extraction is based on the empirical molecular formula and retention time of each first extracted feature, and identifying one or more groups of isotopologues from the second extracted features.
Temporary storage of sample portions for artefact-preventing fluid processing
10 Nov 20
In a method for processing successive fluidic sample portions provided by a sample source, sample reception volumes are filled successively temporarily with at least a respective one of the sample sections, and the sample sections are emptied successively out of the sample reception volumes in such a way, that, while emptying, it is avoided to bring two respective ones of the sample sections, which have not left the sample source directly adjacent to one another, in contact with one another.
Systems and methods for tracking and providing workflow information
10 Nov 20
A tangible computer-readable storage device storing computer-executable program instructions that generate a user interface for displaying workflow information associated with a tissue specimen in a pathology laboratory.
Methods, Devices, and Kits to Improve Reduction or Labeling of Carbohydrates
5 Nov 20
The present invention provides methods, devices, and kits to improve procedures for reducing carbohydrates, such as glycans released from glycoconjugates, or for labeling carbohydrates by reductive amination.